RT Journal Article
SR Electronic
T1 Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 859
OP 866
DO 10.1136/annrheumdis-2020-217871
VO 79
IS 7
A1 Milena Gianfrancesco
A1 Kimme L Hyrich
A1 Sarah Al-Adely
A1 Loreto Carmona
A1 Maria I Danila
A1 Laure Gossec
A1 Zara Izadi
A1 Lindsay Jacobsohn
A1 Patricia Katz
A1 Saskia Lawson-Tovey
A1 Elsa F Mateus
A1 Stephanie Rush
A1 Gabriela Schmajuk
A1 Julia Simard
A1 Anja Strangfeld
A1 Laura Trupin
A1 Katherine D Wysham
A1 Suleman Bhana
A1 Wendy Costello
A1 Rebecca Grainger
A1 Jonathan S Hausmann
A1 Jean W Liew
A1 Emily Sirotich
A1 Paul Sufka
A1 Zachary S Wallace
A1 Jinoos Yazdany
A1 Pedro M Machado
A1 Philip C Robinson
A1 ,
YR 2020
UL http://ard.bmj.com/content/79/7/859.abstract
AB Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.Methods Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.Results A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.Conclusions We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.